Prostate Cancer Early Detection, Version 1.2014
Peter R. Carroll(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), J. Kellogg Parsons(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Gerald L. Andriole(Barnes-Jewish Hospital), Robert R. Bahnson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Daniel A. Barocas(Breast Cancer Research Foundation), William J. Catàlona(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Douglas M. Dahl(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), John W. Davis(The University of Texas MD Anderson Cancer Center), Jonathan I. Epstein(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ruth B. Etzioni(Fox Chase Cancer Center), Veda N. Giri(Bayer (United States)), George P. Hemstreet(Nebraska Medical Center), Mark H. Kawachi(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Paul H. Lange(Seattle Cancer Care Alliance), Kevin R. Loughlin(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), William T. Lowrance(University of Utah), Paul Maroni(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), James L. Mohler(Roswell Park Comprehensive Cancer Center), Todd M. Morgan(University of Michigan), Robert B. Nadler(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Michael Poch(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Chuck Scales(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Terrence M. Shanefelt(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Andrew J. Vickers(Memorial Sloan Kettering Cancer Center), Robert Wake(St. Jude Children's Research Hospital), Dorothy A. Shead(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Maria Ho(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 107Open Access
Abstract
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for men choosing to participate in an early detection program for prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Overall, the 2014 update represents a more streamlined and concise set of recommendations. The panel stratified the age ranges at which initiating testing for prostate cancer should be considered. Indications for biopsy include both a cutpoint and the use of multiple risk variables in combination. In addition to other biomarkers of specificity, the Prostate Health Index has been included to aid biopsy decisions in certain men, given recent FDA approvals.
Related Papers
No related papers found
Powered by citation graph analysis